Drug Profile
DTwP-HepB-Hib vaccine - Crucell/Novartis Vaccines
Alternative Names: DTP-HepB-Hib; DTwP-HepB-Hib; Fully liquid 5-in-1 pentavalent vaccine (Quinvaxem) - Crucell; QuinvaxemLatest Information Update: 12 May 2015
Price :
$50
*
At a glance
- Originator Berna Biotech; Novartis Vaccines
- Developer Crucell; Novartis Vaccines
- Class Bacterial vaccines; Conjugate vaccines; Haemophilus vaccines; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
Most Recent Events
- 01 Apr 2014 Crucell completes a phase III trial in Diphtheria, Pertussis, Tetanus, Hepatitis B and Haemophilus Infections (prevention, in infants) in the Philippines (NCT01917357)
- 05 Aug 2013 Crucell plans a phase III trial for Diphtheria, Pertussis, Tetanus, Hepatitis B and Haemophilus Infections (prevention, in infants) in Philippines (NCT01917357)
- 31 Dec 2011 Phase-III clinical trials in Diphtheria (prevention, in infants) in India (IM)